38194-50-2 | 2-[(1Z)-5-fluoro-1-[(4-methanesulfinylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%	in stock	$15.00	$10.00
1g	98%	in stock	$18.00	$13.00
5g	98%	in stock	$30.00	$21.00
25g	98%	in stock	$73.00	$51.00
100g	98%	in stock	$201.00	$141.00
500g	98%	in stock	$572.00	$400.00

Description

• Catalog Number: AD40821
• Chemical Name: 2-[(1Z)-5-fluoro-1-[(4-methanesulfinylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid
• CAS Number: 38194-50-2
• Molecular Formula: C20H17FO3S
• Molecular Weight: 356.4106
• MDL Number: MFCD00599589
• SMILES: OC(=O)CC1=C(C)/C(=C/c2ccc(cc2)S(=O)C)/c2c1cc(F)cc2
• NSC Number: 757344

Computed Properties

• Complexity: 616
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1
• XLogP3: 3.4

Literature

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities.

  Archives of toxicology 20170101

• New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis.

  British journal of pharmacology 20160601

• Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10.

  Chemico-biological interactions 20150605

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis.

  BMC cancer 20150101

• A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking.

  Journal of molecular modeling 20121201

• Entrapment of human flavin-containing monooxygenase 3 in the presence of gold nanoparticles: TEM, FTIR and electrocatalysis.

  Biochimica et biophysica acta 20121201

• Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

  Oral oncology 20121101

• Beneficial effects of sulindac in focal cerebral ischemia: a positive role in Wnt/β-catenin pathway.

  Brain research 20121030

• Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.

  Cancer causes & control : CCC 20121001

• COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: synthesis, biological evaluation, and mechanism investigation.

  European journal of medicinal chemistry 20121001

• Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis.

  Photochemistry and photobiology 20120901

• Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.

  British journal of pharmacology 20120901

• A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis.

  Urology 20120801

• Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus.

  Brain research 20120727

• Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120701

• Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.

  European journal of medicinal chemistry 20120701

• The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20120701

• Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines.

  Medical oncology (Northwood, London, England) 20120601

• Docosahexaenoic acid sensitizes colon cancer cells to sulindac sulfide-induced apoptosis.

  Oncology reports 20120601

• A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.

  Cancer prevention research (Philadelphia, Pa.) 20120601

• First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

  The Journal of biological chemistry 20120406

• The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.

  British journal of pharmacology 20120401

• Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells.

  Oncology reports 20120401

• Target delivery and controlled release of the chemopreventive drug sulindac by using an advanced layered double hydroxide nanomatrix formulation system.

  Journal of materials science. Materials in medicine 20120401

• Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.

  Biochemical pharmacology 20120315

• Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.

  Journal of medicinal chemistry 20120308

• Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs.

  Toxicology in vitro : an international journal published in association with BIBRA 20120301

• Role of Sulindac and Celecoxib in chemoprevention of colorectal cancer via intrinsic pathway of apoptosis: exploring NHE-1, intracellular calcium homeostasis and Calpain 9.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120301

• In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3.

  Biochemical pharmacology 20120215

• The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells.

  Annals of hematology 20120201

• Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.

  The Journal of pharmacology and experimental therapeutics 20120201

• Muscle relaxants for pain management in rheumatoid arthritis.

  The Cochrane database of systematic reviews 20120118

• DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines.

  International journal of cancer 20120115

• The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.

  FEBS letters 20120102

• Facilitation of human osteoblast apoptosis by sulindac and indomethacin under hypoxic injury.

  Journal of cellular biochemistry 20120101

• Drug-induced chronic pancreatitis.

  Medicine and health, Rhode Island 20120101

• Modulation of apoptosis protein profiles--role of P-gp in HeLa cells exposed to doxorubicin.

  Cancer genomics & proteomics 20120101

• Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?

  TheScientificWorldJournal 20120101

• Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage.

  PloS one 20120101

• Jaded smiles: ancient Mayan dental inlays and today's Central American patients.

  Journal of the Massachusetts Dental Society 20120101

• Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.

  PloS one 20120101

• Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury.

  Toxicology 20111218

• Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

  Cancer research 20111215

• An old NSAID revisited: crystal structure of aldose reductase in complex with sulindac at 1.0 Å supports a novel mechanism for its anticancer and antiproliferative effects.

  ChemMedChem 20111209

• Non steroidal anti-inflammatory drugs modulate the physicochemical properties of plasma membrane in experimental colorectal cancer: a fluorescence spectroscopic study.

  Molecular and cellular biochemistry 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein.

  The Journal of biological chemistry 20111118

• An intermittent approach for cancer chemoprevention.

  Nature reviews. Cancer 20111110

• Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer.

  Molecular carcinogenesis 20111101

• Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).

  Prostaglandins & other lipid mediators 20111101

• Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.

  Cancer prevention research (Philadelphia, Pa.) 20111101

• Novel human mPGES-1 inhibitors identified through structure-based virtual screening.

  Bioorganic & medicinal chemistry 20111015

• The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway.

  Apoptosis : an international journal on programmed cell death 20110901

• FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide.

  The Journal of clinical endocrinology and metabolism 20110901

• A sulindac analogue is effective against malignant pleural effusion in mice.

  Lung cancer (Amsterdam, Netherlands) 20110801

• Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines.

  Toxicology in vitro : an international journal published in association with BIBRA 20110801

• Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin.

  Journal of pharmaceutical sciences 20110801

• Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

  Cancer prevention research (Philadelphia, Pa.) 20110701

• Studies on the metabolism and biological activity of the epimers of sulindac.

  Drug metabolism and disposition: the biological fate of chemicals 20110601

• Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110601

• Sulindac sulfide induces autophagic death in gastric epithelial cells via survivin down-regulation: a mechanism of NSAIDs-induced gastric injury.

  Biochemical pharmacology 20110601

• Of timing and surrogates: a way forward for cancer chemoprevention.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110601

• Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.

  International journal of colorectal disease 20110501

• Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.

  Journal of medicinal chemistry 20110414

• The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.

  British journal of pharmacology 20110401

• Optimisation and validation of a fast HPLC method for the quantification of sulindac and its related impurities.

  Journal of pharmaceutical and biomedical analysis 20110325

• The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon.

  Gut 20110301

• [Antitumor effects of sulindac in ovarian cell cultures].

  Ginekologia polska 20110301

• A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.

  Cancer chemotherapy and pharmacology 20110201

• Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.

  The Journal of pathology 20110201

• Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

  Cancer prevention research (Philadelphia, Pa.) 20110201

• Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.

  Bioorganic & medicinal chemistry 20110201

• Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status.

  Archives of pharmacal research 20110201

• Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.

  Neoplasia (New York, N.Y.) 20110201

• Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20110101

• The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac.

  Cancer prevention research (Philadelphia, Pa.) 20110101

• Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.

  PloS one 20110101

• Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.

  PloS one 20110101

• Effect of sulindac sulfide on metallohydrolases in the human colon cancer cell line HT-29.

  PloS one 20110101

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis.

  Proceedings of the National Academy of Sciences of the United States of America 20101116

• Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.

  Carcinogenesis 20101101

• Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.

  European journal of medicinal chemistry 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

  Journal of the National Cancer Institute 20101006

• Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.

  Gastroenterology 20101001

• Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus.

  Journal of neurochemistry 20101001

• Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.

  Cancer prevention research (Philadelphia, Pa.) 20101001

• Suppression of growth arrest and DNA damage-inducible 45alpha expression confers resistance to sulindac and indomethacin-induced gastric mucosal injury.

  The Journal of pharmacology and experimental therapeutics 20100901

• Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.

  Gastroenterology 20100901

• Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice.

  Cancer prevention research (Philadelphia, Pa.) 20100901

• Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.

  The Journal of pharmacology and experimental therapeutics 20100801

• Induction of p53-independent apoptosis by a novel synthetic hexahydrocannabinol analog is mediated via Sp1-dependent NSAID-activated gene-1 in colon cancer cells.

  Biochemical pharmacology 20100701

• A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model.

  Cancer prevention research (Philadelphia, Pa.) 20100701

• Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment.

  Toxicology 20100604

• R-flurbiprofen suppresses distal nonmucin-producing colorectal tumors in azoxymethane-treated rats, without suppressing eicosanoid production.

  American journal of physiology. Gastrointestinal and liver physiology 20100601

• Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.

  Thyroid : official journal of the American Thyroid Association 20100601

• Radiological reasoning: multiple mesenteric masses.

  AJR. American journal of roentgenology 20100601

• Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer.

  Journal of cancer research and clinical oncology 20100401

• The integrated stress response-associated signals modulates intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/PTGF-beta).

  Carcinogenesis 20100401

• Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor.

  Cancer prevention research (Philadelphia, Pa.) 20100401

• Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer.

  Expert opinion on investigational drugs 20100401

• Bismuth(III) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori.

  Dalton transactions (Cambridge, England : 2003) 20100321

• Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations.

  Cellular and molecular life sciences : CMLS 20100301

• Sulindac sulfone induces a decrease of beta-catenin in HNSCC.

  Anticancer research 20100201

• Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms.

  Medical science monitor : international medical journal of experimental and clinical research 20100101

• Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.

  Cancer prevention research (Philadelphia, Pa.) 20100101

• Possible role of HSP60 in synergistic action of anthracyclines and sulindac in HeLa cells.

  Acta poloniae pharmaceutica 20100101

• The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells.

  Cancer prevention research (Philadelphia, Pa.) 20091201

• Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.

  Molecular cancer therapeutics 20091201

• Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.

  Essays in biochemistry 20091104

• Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo.

  The Journal of surgical research 20091101

• Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.

  Carcinogenesis 20091101

• Up-regulation of GADD45alpha expression by NSAIDs leads to apoptotic and necrotic colon cancer cell deaths.

  Apoptosis : an international journal on programmed cell death 20091101

• Chemical and structural biology to direct the repurposing of sulindac.

  ChemMedChem 20091101

• Flushing out the diagnosis.

  Journal of hospital medicine 20091101

• Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

  Cancer research 20091015

• Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury.

  The Journal of pharmacology and experimental therapeutics 20091001

• Nutrition and colon cancer prevention.

  Current opinion in clinical nutrition and metabolic care 20090901

• Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta.

  Apoptosis : an international journal on programmed cell death 20090701

• The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives.

  Bioorganic & medicinal chemistry letters 20090615

• Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells.

  European journal of pharmacology 20090610

• The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20090601

• Lung tumor promotion by curcumin.

  Carcinogenesis 20090601

• A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

  Cancer prevention research (Philadelphia, Pa.) 20090601

• Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.

  European journal of medicinal chemistry 20090501

• [Role of peroxisome proliferators-activated receptor-gamma in the chemical prevention therapy of sulindac for precancerous lesions of rats].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20090418

• Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.

  Oncology reports 20090401

• Off-label use of approved drugs.

  Nature reviews. Clinical oncology 20090401

• Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.

  Chemico-biological interactions 20090316

• Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.

  Toxicological sciences : an official journal of the Society of Toxicology 20090301

• Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

  Cancer prevention research (Philadelphia, Pa.) 20090301

• A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

  Cancer chemotherapy and pharmacology 20090201

• A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201

• Reducing the risk of recurrent colon polyps.

  Clinical advances in hematology & oncology : H&O 20090201

• NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway.

  International journal of cancer 20090101

• Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.

  Carcinogenesis 20090101

• Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses.

  Journal of drugs in dermatology : JDD 20090101

• Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide.

  Anticancer research 20090101

• Sulindac enhances the killing of cancer cells exposed to oxidative stress.

  PloS one 20090101

• Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms.

  Journal of gastroenterology 20090101

• Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled.

  Angewandte Chemie (International ed. in English) 20090101

• Single dose oral sulindac for acute postoperative pain in adults.

  The Cochrane database of systematic reviews 20090101

• Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.

  Cancer prevention research (Philadelphia, Pa.) 20081201

• The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.

  Cancer research 20081015

• Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

  Journal of medicinal chemistry 20081009

• A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation.

  Lung cancer (Amsterdam, Netherlands) 20080901

• Cellular imaging predictions of clinical drug-induced liver injury.

  Toxicological sciences : an official journal of the Society of Toxicology 20080901

• Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.

  International journal of cancer 20080901

• Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901

• A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

  Clinical genitourinary cancer 20080901

• Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition.

  Journal of medicinal chemistry 20080828

• Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases.

  Oncology reports 20080801

• Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice.

  Carcinogenesis 20080701

• Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells.

  Oncology reports 20080701

• Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.

  Molecular cancer therapeutics 20080701

• Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts.

  Molecular cancer therapeutics 20080701

• Interactions of sulindac and its metabolites with phospholipid membranes: an explanation for the peroxidation protective effect of the bioactive metabolite.

  Free radical research 20080701

• Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.

  International journal of pharmaceutics 20080624

• Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.

  The Journal of biological chemistry 20080620

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.

  Journal of the National Cancer Institute 20080604

• Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

  Cancer prevention research (Philadelphia, Pa.) 20080601

• Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone.

  Cancer prevention research (Philadelphia, Pa.) 20080601

• Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase.

  Neuropharmacology 20080501

• The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB.

  Oncogene 20080417

• Interactions of acetylcholinesterase with caveolin-1 and subsequently with cytochrome c are required for apoptosome formation.

  Carcinogenesis 20080401

• Sulindac suppresses beta-catenin expression in human cancer cells.

  European journal of pharmacology 20080331

• Qualitative and quantitative characterization of the amyloid beta peptide (Abeta) population in biological matrices using an immunoprecipitation-LC/MS assay.

  Journal of neuroscience methods 20080315

• Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways.

  Life sciences 20080312

• Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells.

  International journal of cancer 20080301

• Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.

  Molecular pharmacology 20080301

• Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.

  Molecular pharmacology 20080301

• Comparative bioavailability of sulindac in capsule and tablet formulations.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20080301

• Aseptic meningitis associated with chronic sulindac use for osteoarthritis: a case report.

  Rheumatology international 20080201

• Chemoprevention with special reference to inherited colorectal cancer.

  Familial cancer 20080101

• Unique MAP Kinase binding sites.

  Biochimica et biophysica acta 20080101

• Chemoprevention of arylamine-induced colorectal aberrant crypts.

  Experimental biology and medicine (Maywood, N.J.) 20080101

• SMAC mimetics sensitize nonsteroidal anti-inflammatory drug-induced apoptosis by promoting caspase-3-mediated cytochrome c release.

  Cancer research 20080101

• Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy.

  Advances in experimental medicine and biology 20080101

• Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation.

  Journal of neuroinflammation 20080101

• Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

  Nutrition and cancer 20080101

• The management of desmoids in patients with familial adenomatous polyposis (FAP).

  Acta chirurgica Iugoslavica 20080101

• Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats.

  Yonsei medical journal 20071231

• Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology.

  The Journal of biological chemistry 20071221

• Anti-angiogenic properties of a sulindac analogue.

  British journal of pharmacology 20071201

• New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation.

  Journal of pharmaceutical sciences 20071101

• Use of sulindac in polyhydramnios.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20071101

• Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition.

  Molecular carcinogenesis 20071001

• Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071001

• Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells.

  Toxicology and applied pharmacology 20070901

• The effect of long-term treatment with sulindac on the progression of diabetic retinopathy.

  Current medical research and opinion 20070801

• A case of Cronkhite-Canada syndrome with colorectal adenomas: effect of the nonsteroidal anti-inflammatory drug sulindac.

  The American journal of gastroenterology 20070801

• Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology.

  ACS chemical biology 20070720

• Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.

  International journal of oral and maxillofacial surgery 20070701

• Spontaneous regression of rectal polyps following abdominal colectomy and ileorectal anastomosis for familial adenomatous polyposis, without sulindac treatment: report of four cases.

  Endoscopy 20070701

• Sulindac loaded alginate beads for a mucoprotective and controlled drug release.

  Journal of microencapsulation 20070601

• Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.

  Molecular cancer therapeutics 20070601

• Functionalized magnetic nanoparticles for small-molecule isolation, identification, and quantification.

  Analytical chemistry 20070501

• Sulindac sulfone modulates beta-catenin in human cholesteatoma cell culture.

  Archives of medical research 20070501

• Sulindac treatment in hereditary non-polyposis colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20070501

• Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac.

  Cancer letters 20070418

• JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo.

  European journal of pharmacology 20070410

• Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells.

  Histology and histopathology 20070401

• One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.

  Transfusion 20070401

• Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon.

  Cancer research 20070401

• Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats.

  Life sciences 20070320

• The same gamma-secretase accounts for the multiple intramembrane cleavages of APP.

  Journal of neurochemistry 20070301

• Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.

  Neoplasia (New York, N.Y.) 20070301

• [Effect of peroxisome proliferators-activated receptor-gamma in the mechanisms of sulindac against large intestine carcinoma].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20070218

• Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis.

  Apoptosis : an international journal on programmed cell death 20070201

• A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis (Br J Surg 2006; 93; 1258-1264).

  The British journal of surgery 20070201

• Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin.

  Journal of the American Chemical Society 20070131

• Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells.

  Cancer letters 20070108

• A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20070101

• Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants.

  The Journal of pharmacology and experimental therapeutics 20070101

• Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.

  Apoptosis : an international journal on programmed cell death 20070101

• Effects of non-steroidal anti-inflammatory drugs on blood pressure.

  Journal of hypertension 20070101

• Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition.

  Cancer biology & therapy 20070101

• Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses.

  Archives of pharmacal research 20070101

• Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac.

  Journal of agricultural and food chemistry 20061213

• Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.

  Chemico-biological interactions 20061201

• Sulindac, a nonsteroidal anti-inflammatory drug, selectively inhibits interferon-gamma-induced expression of the chemokine CXCL9 gene in mouse macrophages.

  Biochemical and biophysical research communications 20061117

• Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin.

  Biochemical pharmacology 20061115

• Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels.

  Life sciences 20061110

• Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.

  British journal of haematology 20061101

• p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis.

  Oncology reports 20061101

• Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes.

  The Journal of biological chemistry 20061020

• 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.

  Prostaglandins & other lipid mediators 20061001

• High perinatal survival in monoamniotic twins managed by prophylactic sulindac, intensive ultrasound surveillance, and Cesarean delivery at 32 weeks' gestation.

  Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 20061001

• Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide.

  Basic & clinical pharmacology & toxicology 20061001

• Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents.

  Current drug metabolism 20061001

• Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons.

  Metabolic brain disease 20060901

• A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro.

  Carcinogenesis 20060801

• Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer.

  Oncology reports 20060801

• Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems.

  Fundamental & clinical pharmacology 20060801

• Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

  American journal of clinical oncology 20060801

• Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.

  Clinical therapeutics 20060801

• Proapoptotic activity of NAG-1 is cell type specific and not related to COX-2 expression.

  Apoptosis : an international journal on programmed cell death 20060701

• [Inhibition of gastric cancer cells growth in vitro by sulindac].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701

• Capillary electrophoresis combining field-amplified sample stacking and electroosmotic flow suppressant for analysis of sulindac and its two metabolites in plasma.

  Journal of chromatography. A 20060630

• Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction.

  International journal of oncology 20060601

• Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide.

  International journal of oncology 20060601

• Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• Apoptosis: a relevant tool for anticancer therapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

  Neoplasia (New York, N.Y.) 20060601

• Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).

  Carcinogenesis 20060501

• Novel drug release profiles from micellar solutions of PLA-PEO-PLA triblock copolymers.

  Journal of controlled release : official journal of the Controlled Release Society 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis.

  The Annals of pharmacotherapy 20060501

• Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells.

  Molecular cancer therapeutics 20060501

• Early loss of Fhit in the respiratory tract of rodents exposed to environmental cigarette smoke.

  Cancer research 20060401

• Id-1 gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer.

  International journal of cancer 20060315

• Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.

  Gut 20060301

• Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways.

  Molecular cancer therapeutics 20060301

• Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells.

  The Biochemical journal 20060215

• Inhibitory effects of black tea theaflavin derivatives on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and arachidonic acid metabolism in mouse ears.

  Molecular nutrition & food research 20060201

• [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].

  Ugeskrift for laeger 20060123

• MF tricyclic and sulindac retard tumor formation in an animal model.

  International journal of cancer 20060101

• Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.

  Investigational new drugs 20060101

• The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization.

  Molecular cancer therapeutics 20060101

• Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.

  Journal of gastroenterology and hepatology 20060101

• Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest.

  Anticancer research 20060101

• Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer.

  PloS one 20060101

• COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation.

  Anticancer research 20060101

• Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

  Nutrition and cancer 20060101

• Modulation of multigene expression and proteome profiles by chemopreventive agents.

  Mutation research 20051211

• Modulation of apoptosis by cancer chemopreventive agents.

  Mutation research 20051211

• Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line.

  Oncogene 20051208

• Sulindac suppresses nuclear factor-kappaB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis.

  The Journal of clinical endocrinology and metabolism 20051201

• Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries determine vessel plasticity.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20051201

• Differential gene expression of sulindac-treated human breast epithelial cells.

  International journal of oncology 20051201

• Exisulind in the treatment of prostate cancer.

  Expert review of anticancer therapy 20051201

• Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene.

  The Journal of pharmacology and experimental therapeutics 20051101

• Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC.

  Annals of the New York Academy of Sciences 20051101

• p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse.

  Cancer research 20051015

• Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice.

  International journal of cancer 20051010

• Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice.

  The Journal of pharmacology and experimental therapeutics 20051001

• Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20051001

• Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2.

  Molecular cancer therapeutics 20051001

• Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.

  Molecular cancer therapeutics 20051001

• Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.

  Cancer research 20050915

• Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells.

  Life sciences 20050902

• [The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20050818

• Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling.

  The Journal of biological chemistry 20050805

• The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats.

  Vascular pharmacology 20050801

• Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050715

• Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20050701

• Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20050701

• [Possibilities in the treatment of primary biliary cirrhosis].

  Orvosi hetilap 20050605

• Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB pathway in IgE-dependent mast cell activation.

  Journal of leukocyte biology 20050601

• The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.

  Cell cycle (Georgetown, Tex.) 20050601

• Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.

  Experimental cell research 20050515

• Sulindac induces apoptosis and protects against colon carcinoma in mice.

  World journal of gastroenterology 20050514

• Random mutagenesis of presenilin-1 identifies novel mutants exclusively generating long amyloid beta-peptides.

  The Journal of biological chemistry 20050513

• A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.

  BJU international 20050501

• The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3).

  Molecular cancer therapeutics 20050501

• A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.

  Clinical lung cancer 20050501

• Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.

  Journal of medicinal chemistry 20050407

• Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells.

  International journal of oncology 20050401

• Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.

  Journal of neurochemistry 20050401

• Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.

  Molecular cancer therapeutics 20050401

• Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.

  World journal of gastroenterology 20050328

• Methylation in the p21WAF1/cip1 promoter of Apc+/-, p21+/- mice and lack of response to sulindac.

  Oncogene 20050317

• Inhibition of angiogenesis-relevant receptor tyrosine kinases by sulindac analogues.

  Chembiochem : a European journal of chemical biology 20050301

• Tocolytic therapy and clinical experience. Combination therapy.

  BJOG : an international journal of obstetrics and gynaecology 20050301

• The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15.

  Molecular cancer therapeutics 20050301

• Mechanisms of sulindac-induced apoptosis and cell cycle arrest.

  Cancer letters 20050227

• Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2.

  Journal of cellular biochemistry 20050215

• Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.

  Molecular cancer therapeutics 20050201

• Sulindac sulfide-induced apoptosis in sinonasal cancer cells.

  Acta oto-laryngologica 20050201

• The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells.

  Experimental cell research 20050115

• Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.

  The Journal of pharmacology and experimental therapeutics 20050101

• Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.

  Fertility and sterility 20050101

• Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells.

  Molecular cancer therapeutics 20050101

• Induction and modulation of lung tumors: genomic and transcriptional alterations in cigarette smoke-exposed mice.

  Experimental lung research 20050101

• [Non-steroid anti-inflammatory drugs in the treatment of Alzheimer's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

• Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.

  Oncogene 20041209

• Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

  Journal of the National Cancer Institute 20041201

• Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.

  Cancer research 20041115

• Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041115

• A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041101

• Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

  The Journal of biological chemistry 20041015

• Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis.

  Carcinogenesis 20041001

• Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20041001

• Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines.

  The Prostate 20041001

• Modulation of the transactivation function of nuclear factor-kappaB by lipopolysaccharide in RAW264.7 macrophages.

  International journal of oncology 20041001

• Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone.

  International journal of molecular medicine 20041001

• Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis.

  Gastroenterology 20040901

• Oncogenic Ras promotes butyrate-induced apoptosis through inhibition of gelsolin expression.

  The Journal of biological chemistry 20040827

• Purification and characterization of the human gamma-secretase complex.

  Biochemistry 20040803

• Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.

  Current opinion in allergy and clinical immunology 20040801

• High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.

  Cancer 20040801

• Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid.

  Gastroenterology 20040801

• Nutritional-pharmacological combinations--a novel approach to reducing colon cancer incidence.

  European journal of nutrition 20040801

• Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20040801

• Chemoprevention of carcinogenesis in familial tumors.

  International journal of clinical oncology 20040801

• Induction of transcription by p21Waf1/Cip1/Sdi1: role of NFkappaB and effect of non-steroidal anti-inflammatory drugs.

  Cell cycle (Georgetown, Tex.) 20040701

• Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.

  World journal of gastroenterology 20040701

• Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells.

  Cancer research 20040601

• Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.

  Pharmacotherapy 20040601

• OSI-461 (OSI).

  Current opinion in investigational drugs (London, England : 2000) 20040601

• Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro.

  Journal of experimental & clinical cancer research : CR 20040601

• COX-2 inhibition and colorectal cancer.

  Seminars in oncology 20040401

• -to: Gardiner TA, Anderson HR, Degenhardt T et al. (2003) prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia 46:1269-1275.

  Diabetologia 20040401

• Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice.

  Toxicology and applied pharmacology 20040315

• Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition.

  Journal of cancer research and clinical oncology 20040301

• Drug-induced liver injury.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301

• Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines.

  Molecular cancer therapeutics 20040301

• Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats.

  Neurobiology of aging 20040301

• The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells.

  The Journal of pharmacology and experimental therapeutics 20040201

• High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.

  Cancer 20040201

• Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.

  Gastroenterology 20040201

• Adenomas of the ampulla of vater in familial adenomatous polyposis: Christian Theodore responds.

  Gastroenterology 20040201

• Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening.

  Angewandte Chemie (International ed. in English) 20040116

• Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

  Angewandte Chemie (International ed. in English) 20040116

• Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.

  British journal of cancer 20040112

• Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.

  Cancer biology & therapy 20040101

• Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.

  Anticancer research 20040101

• Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.

  Drugs in R&D 20040101

• Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci.

  Anticancer research 20040101

• Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system.

  Biochemical and biophysical research communications 20031226

• Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest.

  International journal of cancer 20031210

• Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells.

  Apoptosis : an international journal on programmed cell death 20031201

• Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo.

  Annals of the New York Academy of Sciences 20031201

• Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.

  The Journal of biological chemistry 20031128

• Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho.

  Science (New York, N.Y.) 20031114

• Hepatocellular damage from non-steroidal anti-inflammatory drugs.

  QJM : monthly journal of the Association of Physicians 20031101

• The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species.

  Free radical biology & medicine 20031101

• MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.

  Pancreas 20031101

• [Management of duodenal adenomatosis in patients with familial adenomatous polyposis].

  Annales de chirurgie 20031101

• Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031015

• Prostaglandin inhibitors in preterm labour.

  Best practice & research. Clinical obstetrics & gynaecology 20031001

• [Pioglitazone, a peroxisome proliferators-activated receptor gamma ligand, inhibits dimethylhydrazine (DMH) induced aberrant crypt foci in rats].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20031001

• Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915

• Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells.

  The Biochemical journal 20030901

• Systemic genotoxic effects produced by light, and synergism with cigarette smoke in the respiratory tract of hairless mice.

  Carcinogenesis 20030901

• Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug.

  Diabetologia 20030901

• Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.

  International journal of oncology 20030901

• Okadaic acid induces sustained activation of NFkappaB and degradation of the nuclear IkappaBalpha in human neutrophils.

  Archives of biochemistry and biophysics 20030901

• Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells.

  Molecular cancer therapeutics 20030901

• Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity.

  The Journal of biological chemistry 20030822

• Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.

  American journal of clinical oncology 20030801

• Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis.

  The Journal of biological chemistry 20030711

• Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.

  International journal of colorectal disease 20030701

• ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.

  Molecular biology of the cell 20030701

• Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells.

  The Journal of pathology 20030601

• Lactacystin augments the sulindac-induced apoptosis in HT-29 cells.

  Apoptosis : an international journal on programmed cell death 20030601

• Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation.

  The Journal of biological chemistry 20030516

• Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.

  Molecular cancer therapeutics 20030501

• Chemoprevention of colorectal cancer: slow, steady progress.

  Cleveland Clinic journal of medicine 20030401

• A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor.

  American journal of obstetrics and gynecology 20030401

• Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit vascular smooth muscle cell proliferation via differential effects on the cell cycle.

  The Journal of pharmacy and pharmacology 20030401

• [Inhibition of vascular smooth muscle cell proliferation by non-steroidal anti-inflammatory drugs].

  Shi yan sheng wu xue bao 20030401

• Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice.

  Cancer 20030315

• Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations.

  Carcinogenesis 20030301

• Chemoprevention for colorectal tumorigenesis associated with chronic colitis in mice via apoptosis.

  Journal of experimental & clinical cancer research : CR 20030301

• Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).

  European journal of pharmacology 20030214

• Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.

  Cancer research 20030201

• Anti-angiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane.

  Hybridoma and hybridomics 20030201

• The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell.

  Cancer letters 20030128

• What's new in the treatment of advanced prostate cancer?

  European journal of cancer (Oxford, England : 1990) 20030101

• Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac.

  Carcinogenesis 20030101

• Thermodynamic characterization of the binding process of sulindac to human serum albumin.

  Arzneimittel-Forschung 20030101

• New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen.

  Mutation research 20030101

• Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20030101

• Molecular basis of sulindac competition with specific markers for the major binding sites on human serum albumin.

  Arzneimittel-Forschung 20030101

• Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.

  Journal of experimental therapeutics & oncology 20030101

• The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.

  European journal of gastroenterology & hepatology 20021201

• Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model.

  Carcinogenesis 20021201

• No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.

  Scandinavian cardiovascular journal : SCJ 20021201

• Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis.

  Cytokine 20021124

• Chemoprevention of FAP with sulindac.

  Current oncology reports 20021101

• Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs.

  The Journal of pharmacology and experimental therapeutics 20021101

• Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation.

  Biochemical pharmacology 20021101

• Rapid development of colitis in NSAID-treated IL-10-deficient mice.

  Gastroenterology 20021101

• Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention.

  Cancer research 20021101

• Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane.

  Journal of cancer research and clinical oncology 20021101

• Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays.

  Physiological genomics 20021029

• Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.

  Cancer research 20021015

• Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021001

• Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161: report of a case.

  Diseases of the colon and rectum 20021001

• Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

  Mutation research 20020930

• A mouse model of human oral-esophageal cancer.

  The Journal of clinical investigation 20020915

• Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.

  Oncogene 20020905

• Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents.

  Carcinogenesis 20020901

• [Nonsteroidal anti-inflammatory drugs and the risk of polyposis, colon carcinoma and rectal carcinoma].

  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 20020901

• Sulindac in familial adenomatous polyposis.

  The New England journal of medicine 20020822

• [Rectal carcinoma in a patient with familial adenomatous polyposis coli after colectomy with ileorectal anastomosis and consecutive chemoprevention with sulindac suppositories].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20020801

• Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G.

  Molecular cancer therapeutics 20020801

• Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20020701

• Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers.

  Gastroenterology 20020701

• Sulindac derivative-induced apoptosis in a human umbilical vein endothelial cell line ECV304.

  Chinese medical journal 20020701

• Novel clinical trials in androgen-independent prostate cancer.

  Clinical prostate cancer 20020601

• Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue.

  Gastroenterology 20020501

• PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells.

  International journal of cancer 20020420

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Primary chemoprevention of familial adenomatous polyposis with sulindac.

  The New England journal of medicine 20020404

• Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?

  The New England journal of medicine 20020404

• Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.

  Gastroenterology 20020401

• CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells.

  Molecular cancer therapeutics 20020401

• Expression profile analysis of colon cancer cells in response to sulindac or aspirin.

  Biochemical and biophysical research communications 20020329

• Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).

  Cancer research 20020315

• The new sulindac derivative IND 12 reverses Ras-induced cell transformation.

  Cancer research 20020315

• Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane.

  Cancer letters 20020308

• Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.

  Gastroenterology 20020301

• Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

• Induction of apoptosis by sulindac in azoxymethane-induced possible colonic premalignant lesions in rats.

  Japanese journal of cancer research : Gann 20020301

• Observation on the therapeutic effect of Shu Feng Huo Luo Pian for treatment of osseous arthritis.

  Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 20020301

• New indene-derivatives with anti-proliferative properties.

  Bioorganic & medicinal chemistry letters 20020225

• The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.

  Cancer research 20020215

• GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells.

  Cancer research 20020215

• Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells.

  Biochemical and biophysical research communications 20020208

• Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020201

• Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.

  Seminars in oncology 20020201

• [Experimental study on sulindac metabolites -induced apoptosis on human umbilical vein endothelial cell line ECV304].

  Zhonghua fu chan ke za zhi 20020201

• [Chemoprevention of colorectal cancer].

  Presse medicale (Paris, France : 1983) 20020126

• Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.

  Cancer research 20020115

• Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways.

  Cancer letters 20020110

• Prevention and chemoprevention of colorectal neoplasms.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20020101

• Resistance to apoptosis is increased during metastatic dissemination of colon cancer.

  Clinical & experimental metastasis 20020101

• Sulindac induces apoptosis, inhibits proliferation and activates caspase-3 in Hep G2 cells.

  Anticancer research 20020101

• Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse.

  Biological research 20020101

• [The growth inhibition of colorectal adenoma cells by sulindac and its mechanisms].

  Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao 20020101

• beta-Catenin signaling: therapeutic strategies in oncology.

  Cancer biology & therapy 20020101

• Protein phosphatase 2A interacts with and directly dephosphorylates RelA.

  The Journal of biological chemistry 20011221

• Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro.

  Genes & development 20011215

• Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells.

  World journal of gastroenterology 20011215

• Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II.

  Melanoma research 20011201

• Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Chemopreventive agents inhibit aberrant proliferation of the aneuploid phenotype in a colon epithelial cell line established from Apc 1638N [+/-] mouse.

  Annals of the New York Academy of Sciences 20011201

• Nerve pathology in the type 1 diabetic dog: effects of treatment with sulindac.

  Journal of the peripheral nervous system : JPNS 20011201

• Sulindac inhibited gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in T24 human bladder tumor cells.

  Urological research 20011201

• A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.

  Nature 20011108

• Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.

  The Journal of pharmacology and experimental therapeutics 20011101

• Complete regression of colonic adenomas after treatment with sulindac in Gardner's syndrome: a 4-year follow-up.

  Journal of gastroenterology 20011101

• A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line.

  The Journal of biological chemistry 20011019

• Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase.

  Cancer research 20011015

• Sulindac to prevent recurrent preterm labor: a randomized controlled trial.

  Obstetrics and gynecology 20011001

• Exisulind, a selective apoptotic antineoplastic drug.

  Expert opinion on investigational drugs 20011001

• Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.

  East African medical journal 20011001

• Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis.

  Oncogene 20010927

• Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.

  Cancer research 20010915

• Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.

  The Journal of urology 20010901

• Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.

  The Journal of pharmacology and experimental therapeutics 20010901

• Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1.

  Mutation research 20010901

• Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29.

  Experimental cell research 20010815

• Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.

  Cancer research 20010815

• p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo.

  Cancer research 20010815

• Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.

  Diseases of the colon and rectum 20010801

• Docetaxel and exisulind in hormone-refractory prostate cancer.

  Seminars in oncology 20010801

• Sulindac-associated choledocholithiasis.

  The American journal of gastroenterology 20010701

• Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy.

  Diseases of the colon and rectum 20010701

• Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells.

  International journal of cancer 20010615

• Antiproliferative effects of nitrosulindac on human colon adenocarcinoma cell lines.

  Biochemical and biophysical research communications 20010615

• Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression.

  Cancer research 20010615

• Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.

  Carcinogenesis 20010601

• Prolonged activation of mitogen-activated protein kinases during NSAID-induced apoptosis in HT-29 colon cancer cells.

  International journal of colorectal disease 20010601

• Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.

  Cancer research 20010515

• Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy.

  Kidney international 20010501

• Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.

  The European journal of surgery = Acta chirurgica 20010501

• Sulindac and its derivatives: a novel class of anticancer agents.

  Current opinion in investigational drugs (London, England : 2000) 20010501

• Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.

  Cancer research 20010415

• Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells.

  Biochemical and biophysical research communications 20010406

• Proapoptotic anti-inflammatory drugs.

  Urology 20010401

• Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation.

  Cancer research 20010315

• Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.

  Cancer research 20010215

• Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.

  Cancer research 20010215

• Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20010201

• Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide.

  Cancer research 20010115

• Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.

  Carcinogenesis 20010101

• Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice.

  Journal of cancer research and clinical oncology 20010101

• Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.

  Electrophoresis 20010101

• Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20010101

• Induction of apoptosis by sulindac sulfide in HL60 cells is enhanced by p21CiP1 or p27KiP1.

  Anticancer research 20010101

• Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac.

  International journal of cancer 20001215

• Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane.

  Gut 20001201

• Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.

  Cancer research 20001201

• Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.

  Journal of gastroenterology and hepatology 20001201

• Role of BAX in the apoptotic response to anticancer agents.

  Science (New York, N.Y.) 20001103

• Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20001001

• Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways.

  The Journal of biological chemistry 20000908

• [A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy].

  Ryumachi. [Rheumatism] 20000801

• 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells.

  Journal of the National Cancer Institute 20000719

• Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta).

  Molecular and cellular biology 20000701

• Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.

  Cancer research 20000701

• Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells.

  Gastroenterology 20000601

• Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20000301

• Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.

  Cancer research 20000215

• Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation.

  American journal of physiology. Gastrointestinal and liver physiology 20000201

• Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen.

  Life sciences 20000114

• A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea--a review.

  Cancer detection and prevention 20000101

• PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

  Cell 19991029

• Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.

  Gastroenterology 19991001

• Sulindac inhibits activation of the NF-kappaB pathway.

  The Journal of biological chemistry 19990917

• Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.

  Cancer research 19990901

• Drug-associated cholelithiasis: a case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones.

  The American journal of gastroenterology 19990801

• Green tea and cancer chemoprevention.

  Mutation research 19990716

• Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.

  Cancer research 19990715

• Nitric oxide prevents anoxia-induced apoptosis in colonic HT29 cells.

  Archives of biochemistry and biophysics 19990615

• Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes.

  Cytokine 19990501

• Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19990401

• Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.

  Carcinogenesis 19990401

• Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon.

  Biochimica et biophysica acta 19980824

• Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.

  Cancer research 19970615

• Renal impairment after acute diclofenac, naproxen, and sulindac overdoses.

  Journal of toxicology. Clinical toxicology 19950101

• The influence of sulindac on experimental streptozotocin-induced diabetic neuropathy.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 19940801

• [Acute immunoallergic hemolytic anemia induced by sulindac].

  La Revue de medecine interne 19940301

• Sulindac-induced immune hemolytic anemia.

  Transfusion 19940301

• [Development of Stevens-Johnson syndrome following sulindac administration in a patient with mixed connective tissue disease].

  Ryumachi. [Rheumatism] 19931001

• Naproxen-induced recurrent aseptic meningitis.

  DICP : the annals of pharmacotherapy 19911101

• Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis.

  The American journal of medicine 19900901

• Aplastic anaemia associated with a non-steroidal anti-inflammatory drug: relapse after exposure to another such drug.

  BMJ (Clinical research ed.) 19900707

• Auditory and visual hallucinations associated with sulindac: focus on prostaglandin synthesis and psychotic symptoms.

  Psychosomatics 19900101

• Sulindac-induced aseptic meningitis in mixed connective tissue disease.

  Clinical neurology and neurosurgery 19890101

• Recurrent sulindac-induced aseptic meningitis in a patient tolerant to other nonsteroidal anti-inflammatory drugs.

  Southern medical journal 19881101

• Renal failure and nephrotic syndrome associated with sulindac.

  Clinical nephrology 19880701

• Non-steroidal anti-inflammatory nephrotoxicity.

  Annals of clinical and laboratory science 19880101

• Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacin.

  Nephron 19880101

• Acute cholangitis and pancreatitis associated with sulindac (clinoril).

  Histopathology 19870601

• Hyperkalemia associated with sulindac therapy.

  The Journal of rheumatology 19861201

• Encephalopathy associated with sulindac.

  Human toxicology 19860101

• Sulindac is not renal sparing in man.

  Clinical pharmacology and therapeutics 19850901

• Sulindac hepatotoxicity: effects of acute and chronic exposure.

  Australian and New Zealand journal of medicine 19850801

• Immune hemolytic anemia associated with sulindac.

  Archives of internal medicine 19850801

• Acute renal effects of sulindac and indomethacin in chronic renal failure.

  Clinical pharmacology and therapeutics 19850401

• Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.

  The Journal of clinical investigation 19850101

• Hypersensitivity reaction to sulindac (Clinoril).

  Archives of internal medicine 19841101

• Anaphylactic reaction associated with sulindac.

  Annals of emergency medicine 19840601

• Sulindac-induced acute interstitial nephritis.

  The New Zealand medical journal 19840411

• Renal papillary necrosis due to naproxen.

  The Journal of rheumatology 19840201

• Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.

  Pharmacology 19840101

• Temporary hearing loss induced by combinations of intense sounds and nonsteroidal anti-inflammatory drugs.

  American journal of otolaryngology 19840101

• Sulindac-induced meningitis in mixed connective tissue disease.

  Southern medical journal 19830901

• Recurrent aseptic meningitis due to sulindac.

  Annals of internal medicine 19830901

• Sulindac and renal impairment.

  JAMA 19830603

• Peripheral neuropathy after concomitant administration of dimethyl sulfoxide and sulindac.

  Arthritis and rheumatism 19830601

• Effect of prostaglandin synthetase inhibitors on non-analgesic actions of morphine.

  European journal of pharmacology 19830520

• Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug.

  JAMA 19821203

• Peripheral neuropathy after concomitant dimethyl sulfoxide use and sulindac therapy.

  Archives of physical medicine and rehabilitation 19821101

• Sulindac hepatotoxicity.

  Gut 19821001

• Papillary necrosis mimicking staghorn calculi.

  Urology 19820901

• Cholestatic jaundice caused by sulindac.

  Canadian journal of surgery. Journal canadien de chirurgie 19820501

• Sulindac-induced aseptic meningitis.

  Archives of internal medicine 19820101

• Sulindac (Clinoril) hepatitis.

  Gastroenterology 19810301

• Nephrotic syndrome associated with sulindac.

  The New England journal of medicine 19810212

• Myasthenia gravis and penicillamine therapy of rheumatoid arthritis.

  JAMA 19801017

• Sulindac-induced bone marrow toxicity.

  Lancet (London, England) 19801011

• Hypertensive reaction with sulindac.

  Canadian Medical Association journal 19800607

• Delirium associated with sulindac.

  JAMA 19800425

• Marrow aplasia and sulindac.

  Annals of internal medicine 19800101

• [Ionized fluorine in the plasma and urine of subjects treated with organofluorine drugs prescribed in rheumatology].

  Revue du rhumatisme et des maladies osteo-articulaires 19790201